Ep 62: Post PD-1 studies

SummaryOn mountain emergencies...Sapna's had them, James denies them...This conversation delves into the treatment options available for patients with advanced melanoma who have progressed after anti PD-1 therapy. The discussion covers various clinical studies, response rates, and the implications of combination therapy post-PD1 progression. James and Sapna conclude that while combination therapies show promise, the responses may not be as robust as those seen in frontline treatments.Keywordsmelanoma, PD-1, treatment, clinical trials, immunotherapy, BRAF, response rates, efficacy, combination therapy, patient outcomesTakeawaysThe conversation focuses on treatment options after PD-1 progression.Clinical studies provide valuable data on post-PD-1 therapies.Response rates for combination therapies are generally higher than monotherapy.BRAF status is a critical factor in treatment decisions.Randomized studies help clarify the efficacy of different treatment approaches.Combination therapy may offer better outcomes for patients post-PD-1.Acquired resistance remains a challenge.TitlesExploring Treatment Options Beyond PD-1The Role of Clinical Trials in Melanoma TherapySound Bites"What to do post PD-1 exposure?""Can you get a response to IPI after PD-1?""The primary endpoint was PFS, not ORR... "Chapters00:00 Opening theme music (My Favourite Dress by The Wedding Present)01:25 Mountain rescue quickfire03:08 Post anti-PD1 studies - the issues04:13 Pires da Silva retrospective study08:53 Olson single-arm prospective study (and yes we see you Jason)10:38 SWOG S1616 randomized ph 2 study16:35 Conclusions17:17 Fact Check